Author

Geert J.A. Wanten

EARLY RESPONSE TO GLEPAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOG, IN SHORT BOWEL SYNDROME PATIENTS WITH INTESTINAL FAILURE: RESULTS OF 24-WEEK PHASE 3 TRIAL
EARLY RESPONSE TO GLEPAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOG, IN SHORT BOWEL SYNDROME PATIENTS WITH INTESTINAL FAILURE: RESULTS OF 24-WEEK PHASE 3 TRIAL

Geert J.A. Wanten  et al.

ESPEN guidelines on chronic intestinal failure in adults
ESPEN guidelines on chronic intestinal failure in adults

Geert J.A. Wanten  et al.

Item 1 - 2 / 2
1